COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link
- 8 July 2015
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (4), 635-648
- https://doi.org/10.1111/bph.13198
Abstract
Cigarette smoking has reached epidemic proportions within many regions of the world and remains the highest risk factor for chronic obstructive pulmonary disease (COPD) and lung cancer. Squamous cell lung cancer is commonly detected in heavy smokers, where the risk of developing lung cancer is not solely defined by tobacco consumption. Although therapies that target common driver mutations in adenocarcinomas are showing some promise, they are proving ineffective in smoking-related squamous cell lung cancer. Since COPD is characterized by an excessive inflammatory and oxidative stress response, this review details how aberrant innate, adaptive and systemic inflammatory processes can contribute to lung cancer susceptibility in COPD. Activated leukocytes release increasing levels of proteases and free radicals as COPD progresses and tertiary lymphoid aggregates accumulate with increasing severity. Reactive oxygen species promote formation of reactive carbonyls that are not only tumourigenic through initiating DNA damage, but can directly alter the function of regulatory proteins involved in host immunity and tumour suppressor functions. Systemic inflammation is also markedly increased during infective exacerbations in COPD and the interplay between tumour-promoting serum amyloid A (SAA) and IL-17A is discussed. SAA is also an endogenous allosteric modifier of FPR2 expressed on immune and epithelial cells, and the therapeutic potential of targeting this receptor is proposed as a novel strategy for COPD-lung cancer overlap.Funding Information
- Australian Research Council
- National Health and Medical Research Council
This publication has 141 references indexed in Scilit:
- Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)Lung Cancer, 2012
- Pharmacological antioxidant strategies as therapeutic interventions for COPDBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesisNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid ANature Immunology, 2010
- Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patientsLung Cancer, 2010
- Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growthNature Medicine, 2010
- Alpha1-Antitrypsin Deficiency Carriers, Tobacco Smoke, Chronic Obstructive Pulmonary Disease, and Lung Cancer RiskArchives of Internal Medicine, 2008
- The Biological Functions of T Helper 17 Cell Effector Cytokines in InflammationImmunity, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002